Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas

P. Janovská, V. Bryja,

. 2017 ; 174 (24) : 4701-4715. [pub] 20170830

Language English Country England, Great Britain

Document type Journal Article, Review

Grant support
NV15-29793A MZ0 CEP Register

Digital library NLK
Full text - Article
Source

E-resources Online Full text

NLK Free Medical Journals from 1968 to 1 year ago
PubMed Central from 1968 to 2020
Europe PubMed Central from 1968 to 1 year ago
Medline Complete (EBSCOhost) from 2002-01-01 to 1 year ago
Wiley Free Content from 1997 to 1 year ago

In this review, we discuss the intricate roles of the Wnt signalling network in the development and progression of mature B-cell-derived haematological malignancies, with a focus on chronic lymphocytic leukaemia (CLL) and related B-cell lymphomas. We review the current literature and highlight the differences between the β-catenin-dependent and -independent branches of Wnt signalling. Special attention is paid to the role of the non-canonical Wnt/planar cell polarity (PCP) pathway, mediated by the Wnt-5-receptor tyrosine kinase-like orphan receptor (ROR1)-Dishevelled signalling axis in CLL. This is mainly because the Wnt/PCP co-receptor ROR1 was found to be overexpressed in CLL and the Wnt/PCP pathway contributes to numerous aspects of CLL pathogenesis. We also discuss the possibilities of therapeutically targeting the Wnt signalling pathways as an approach to disrupt the crucial interaction between malignant cells and their micro-environment. We also advocate the need for research in this direction for other lymphomas, namely, diffuse large B-cell lymphoma, Hodgkin lymphoma, mantle cell lymphoma, Burkitt lymphoma and follicular lymphoma where the Wnt signalling pathway probably plays a similar role. LINKED ARTICLES: This article is part of a themed section on WNT Signalling: Mechanisms and Therapeutic Opportunities. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.24/issuetoc.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18033834
003      
CZ-PrNML
005      
20201031182456.0
007      
ta
008      
181008s2017 enk f 000 0|eng||
009      
AR
024    7_
$a 10.1111/bph.13949 $2 doi
035    __
$a (PubMed)28703283
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a enk
100    1_
$a Janovská, Pavlína $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
245    10
$a Wnt signalling pathways in chronic lymphocytic leukaemia and B-cell lymphomas / $c P. Janovská, V. Bryja,
520    9_
$a In this review, we discuss the intricate roles of the Wnt signalling network in the development and progression of mature B-cell-derived haematological malignancies, with a focus on chronic lymphocytic leukaemia (CLL) and related B-cell lymphomas. We review the current literature and highlight the differences between the β-catenin-dependent and -independent branches of Wnt signalling. Special attention is paid to the role of the non-canonical Wnt/planar cell polarity (PCP) pathway, mediated by the Wnt-5-receptor tyrosine kinase-like orphan receptor (ROR1)-Dishevelled signalling axis in CLL. This is mainly because the Wnt/PCP co-receptor ROR1 was found to be overexpressed in CLL and the Wnt/PCP pathway contributes to numerous aspects of CLL pathogenesis. We also discuss the possibilities of therapeutically targeting the Wnt signalling pathways as an approach to disrupt the crucial interaction between malignant cells and their micro-environment. We also advocate the need for research in this direction for other lymphomas, namely, diffuse large B-cell lymphoma, Hodgkin lymphoma, mantle cell lymphoma, Burkitt lymphoma and follicular lymphoma where the Wnt signalling pathway probably plays a similar role. LINKED ARTICLES: This article is part of a themed section on WNT Signalling: Mechanisms and Therapeutic Opportunities. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v174.24/issuetoc.
650    _2
$a zvířata $7 D000818
650    _2
$a lidé $7 D006801
650    _2
$a chronická lymfatická leukemie $x diagnóza $x metabolismus $7 D015451
650    _2
$a B-buněčný lymfom $x diagnóza $x metabolismus $7 D016393
650    12
$a signální dráha Wnt $7 D060449
655    _2
$a časopisecké články $7 D016428
655    _2
$a přehledy $7 D016454
700    1_
$a Bryja, Vítězslav $u Institute of Experimental Biology, Faculty of Science, Masaryk University, Brno, Czech Republic.
773    0_
$w MED00009383 $t British journal of pharmacology $x 1476-5381 $g Roč. 174, č. 24 (2017), s. 4701-4715
856    41
$u https://pubmed.ncbi.nlm.nih.gov/28703283 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20201031182456 $b ABA008
999    __
$a ok $b bmc $g 1340315 $s 1030828
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2017 $b 174 $c 24 $d 4701-4715 $e 20170830 $i 1476-5381 $m British journal of pharmacology $n Br J Pharmacol $x MED00009383
GRA    __
$a NV15-29793A $p MZ0
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...